+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 50Years
All Genders
Healthy Volunteers
ID07698600

Testing Safety and Immune Response of the RNA Vaccine BNT168 in Adults With or Without HIV A Randomized, Placebo-Controlled Clinical Trial

Led by BioNTech SE · Updated on 2026-10-14

126

Participants Needed

4

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the RNA-based vaccine BNT168 in adults aged 18 to 50 years both living with and without HIV. This Phase I, randomized, placebo-controlled, double-blind study aims to assess the vaccines safety, immune response, and impact on the amount of virus present. The study includes people living without HIV PLWOH and people living with HIV PLWH on stable antiretroviral therapy, with some participants undergoing treatment interruption to study viral control. The study involves multiple cohorts randomized to receive either BNT168 or a placebo. PLWOH participants receive three intramuscular injections in the same arm over approximately two months, followed by about six months of follow-up. PLWH participants receive four injections over about six months, including a period of analytical treatment interruption ATI to assess viral kinetics, followed by resumption of therapy and a six-month follow-up. The vaccine is given via intramuscular injection into the deltoid muscle. Participants will be involved in screening, treatment, and follow-up phases lasting approximately 9 months for PLWOH and up to 13 months for PLWH. Researchers will monitor safety by tracking adverse events and immune responses, including T cell activity and viral load changes during ATI. Safety assessments include observation of local and systemic reactions after each dose. The study also measures changes in CD4 T cell counts and time to loss of viral control, with ongoing safety monitoring through the study end.

CONDITIONS

Brief Title

A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV

Research Team

B

BioNTech clinical trials patient information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here